MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale and
maturity of marketable...
$4,700K
Net cash provided by
investing activities
$4,700K
Increase in cash and cash
equivalents
$604K
Canceled cashflow
$4,096K
Stock-based compensation
$474K
Trade receivables,
prepaid expenses and...
-$202K
Depreciation
$6K
Net cash used in
operating activities
-$4,081K
Net cash used in
financing activities
-$15K
Canceled cashflow
$682K
Net loss
-$3,585K
Trade payables,
accrued expenses,...
-$1,160K
Withholdings from exercise of
options and issuance of...
-$15K
Amortization of premium or
discount on marketable...
-$18K
Loss from continuing
operations
-$3,585K
Other income, net
$231K
Loss from continuing
operations before income...
-$3,585K
Canceled cashflow
$231K
Royalty
revenues-Royalty
$86K
Operating loss
-$3,816K
Canceled cashflow
$86K
Total operating
expenses
$3,902K
General and
administrative
$3,085K
Other segment items
$473K
Research and
development-Research And Development...
$194K
Research and
development-Repibresib VYN201
$150K
Back
Back
Cash Flow
VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. (VYNE)
source: myfinsight.com